| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0304-419X(02)00036-7 |
| P698 | PubMed publication ID | 11960695 |
| P50 | author | Javier León | Q58303371 |
| Martin Eilers | Q37383629 | ||
| P2093 | author name string | Werner Lutz | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| GADD45 induction of a G2/M cell cycle checkpoint | Q22009111 | ||
| Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors | Q22010918 | ||
| Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway? | Q22254702 | ||
| The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins | Q24328753 | ||
| Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. | Q24529832 | ||
| MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network | Q24551066 | ||
| The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc | Q24554343 | ||
| Creation of human tumour cells with defined genetic elements | Q28141602 | ||
| Analysis of C-MYC function in normal cells via conditional gene-targeted mutation | Q28143481 | ||
| Repression of p15INK4b expression by Myc through association with Miz-1 | Q28210023 | ||
| Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes | Q28265486 | ||
| Myc activates telomerase | Q28505489 | ||
| Induction of apoptosis in fibroblasts by c-myc protein | Q29614346 | ||
| Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization | Q29614701 | ||
| Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF | Q29619663 | ||
| c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations | Q31929763 | ||
| The MYC protein activates transcription of the alpha-prothymosin gene. | Q33515603 | ||
| Reversible tumorigenesis by MYC in hematopoietic lineages | Q33874286 | ||
| CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex | Q33909938 | ||
| Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins | Q33921667 | ||
| c-Myc overexpression uncouples DNA replication from mitosis | Q33958873 | ||
| Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics | Q33962085 | ||
| The Max network gone mad. | Q33967079 | ||
| MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification | Q33997297 | ||
| Cellular senescence: mitotic clock or culture shock? | Q34019131 | ||
| Specific protection against breast cancers by cyclin D1 ablation | Q34082446 | ||
| Deconstructing myc. | Q34340669 | ||
| Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program | Q34637234 | ||
| Identification of CDK4 as a target of c-MYC. | Q35051802 | ||
| Escape from premature senescence is not sufficient for oncogenic transformation by Ras. | Q54021692 | ||
| Myc represses the growth arrest gene gadd45 | Q58327259 | ||
| Angiogenesis is an early event in the generation of myc-induced lymphomas | Q60456749 | ||
| Genomic instability in Gadd45a-deficient mice | Q62746002 | ||
| Expression of P27KIP1 is prognostic and independent ofMYCN amplification in human neuroblastoma | Q63407032 | ||
| Correlating telomerase activity levels with human neuroblastoma outcomes | Q71803058 | ||
| Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication | Q74083325 | ||
| Myc requires distinct E2F activities to induce S phase and apoptosis | Q74394147 | ||
| The INK4a/ARF tumor suppressor: one gene--two products--two pathways | Q77362259 | ||
| Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion | Q77847672 | ||
| Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions | Q35076939 | ||
| Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. | Q35080744 | ||
| Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion | Q35107957 | ||
| Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis | Q35114477 | ||
| Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression | Q35202114 | ||
| A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest | Q35207580 | ||
| Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization | Q35207910 | ||
| Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis | Q35208288 | ||
| Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. | Q35267304 | ||
| c-Myc transactivation of LDH-A: implications for tumor metabolism and growth | Q36238451 | ||
| Differential modulation of cyclin gene expression by MYC | Q36258572 | ||
| Transient excess of MYC activity can elicit genomic instability and tumorigenesis | Q36455522 | ||
| c-Myc enhances protein synthesis and cell size during B lymphocyte development | Q36668198 | ||
| Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. | Q36786710 | ||
| Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. | Q37623433 | ||
| The transcriptional program of a human B cell line in response to Myc | Q38305262 | ||
| Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). | Q38319947 | ||
| Myc and Max associate in vivo | Q38331177 | ||
| TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b | Q39420254 | ||
| Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. | Q39446946 | ||
| Coexamination of site-specific transcription factor binding and promoter activity in living cells | Q39449417 | ||
| Myc and Max proteins possess distinct transcriptional activities | Q39499398 | ||
| Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals | Q40023280 | ||
| Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events | Q40387972 | ||
| Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. | Q40424280 | ||
| The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. | Q40874517 | ||
| c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells | Q40878189 | ||
| Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras | Q40887247 | ||
| Gene-target recognition among members of the myc superfamily and implications for oncogenesis | Q40902861 | ||
| Control of cell growth by c-Myc in the absence of cell division | Q40919064 | ||
| C-myc overexpression and p53 loss cooperate to promote genomic instability | Q40973006 | ||
| Cdc25 cell-cycle phosphatase as a target of c-myc | Q41175989 | ||
| Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. | Q41414258 | ||
| Oncogenic activity of the c-Myc protein requires dimerization with Max. | Q41577770 | ||
| Deregulated cyclin E induces chromosome instability | Q41692394 | ||
| Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals | Q42817314 | ||
| Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation | Q47987665 | ||
| Drosophila myc regulates cellular growth during development. | Q52573250 | ||
| Telomeres. Bumps on the road to immortality. | Q53429057 | ||
| Role of the INK4a locus in tumor suppression and cell mortality. | Q53455197 | ||
| Inhibition of ras-induced proliferation and cellular transformation by p16INK4. | Q53466632 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 61-71 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Contributions of Myc to tumorigenesis | |
| P478 | volume | 1602 |
| Q38307117 | A spectroscopic investigation of the interaction between c-MYC DNA and tetrapyridinoporphyrazinatozinc(II). |
| Q38185363 | B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies |
| Q34405013 | Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation |
| Q34667820 | C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. |
| Q42391583 | C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas |
| Q39954044 | C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells |
| Q82661563 | C-myc as a predictive marker for chemotherapy in metastatic breast cancer |
| Q35052598 | Control of cellular senescence by CPEB |
| Q28577895 | Cooperative action of multiple cis-acting elements is required for N-myc expression in branchial arches: specific contribution of GATA3 |
| Q28566937 | Coordinated regulation of c-Myc and Max in rat liver development |
| Q38866151 | Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. |
| Q41186543 | Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways |
| Q37051064 | DNA secondary structures: stability and function of G-quadruplex structures |
| Q35562505 | Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex |
| Q92519704 | Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway |
| Q26853567 | Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis |
| Q36668486 | Gene expression regulation and cancer |
| Q36380915 | Glioma: what is the role of c-Myc, hsp90 and telomerase? |
| Q34103991 | High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle |
| Q55065541 | Identification of Biological Targets of Therapeutic Intervention for Hepatocellular Carcinoma by Integrated Bioinformatical Analysis. |
| Q35669176 | Identification of cis-Regulatory Elements in the dmyc Gene of Drosophila Melanogaster |
| Q47280460 | Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen |
| Q37246798 | Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. |
| Q24675943 | Increased expression of a Myc target gene Mina53 in human colon cancer |
| Q36873801 | Investigation of dmyc Promoter and Regulatory Regions |
| Q24540264 | L-Myc protein synthesis is initiated by internal ribosome entry |
| Q36051061 | Liver hyperplasia after tamoxifen induction of Myc in a transgenic medaka model |
| Q64061957 | MYC Oncogene Contributions to Release of Cell Cycle Brakes |
| Q34745850 | MYC deregulation in gastric cancer and its clinicopathological implications. |
| Q26828446 | Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies? |
| Q39776556 | Mutual interference of adenovirus infection and myc expression |
| Q34766868 | Myc influences global chromatin structure. |
| Q41354231 | Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest |
| Q38324237 | Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis |
| Q36367230 | N-myc coordinates retinal growth with eye size during mouse development. |
| Q37507524 | Nucleic acid clamp-mediated recognition and stabilization of the physiologically relevant MYC promoter G-quadruplex |
| Q36326991 | Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth |
| Q33755366 | Potential effects of Mina53 on tumor growth in human pancreatic cancer |
| Q36184999 | Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. |
| Q50673128 | SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties. |
| Q34685327 | SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. |
| Q39296941 | Silencing of the hTERT gene through RNA interference induces apoptosis via bax/bcl-2 in human glioma cells |
| Q27674707 | Solution Structure of a 2:1 Quindoline–c-MYC G-Quadruplex: Insights into G-Quadruplex-Interactive Small Molecule Drug Design |
| Q33193145 | Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions |
| Q33460916 | Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function |
| Q34174883 | Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? |
| Q34352558 | Targeting MYC Expression through G-Quadruplexes |
| Q50903604 | Targeting human c-Myc promoter duplex DNA with actinomycin D by use of multi-way analysis of quantum-dot-mediated fluorescence resonance energy transfer. |
| Q89707146 | The influencing factors and functions of DNA G-quadruplexes |
| Q37631442 | The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics |
| Q41764558 | Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis |
| Q42225304 | Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance |
| Q59796275 | ZNF121 interacts with ZBRK1 and BRCA1 to regulate their target genes in mammary epithelial cells |
| Q42115767 | c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle |
| Q24338852 | c-Myc interacts with TRF1/PIN2 and regulates telomere length |
| Q35928497 | c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells |
| Q36798725 | p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells |
Search more.